Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice Mónica Calderón-Goercke , Javier Loricera , Vicente Aldasoro , Santos Castañeda , Ignacio Villa , Alicia Humbría , Clara Moriano , Susana Romero-Yuste , Javier Narváez , Catalina Gómez-Arango , Eva Pérez-Pampín , Rafael Melero , Elena Becerra-Fernández , Marcelino Revenga , Noelia Álvarez-Rivas , Carles Galisteo , Francisca Sivera , Alejandro Olivé-Marqués , María Álvarez del Buergo , Luisa Marena-Rojas , Carlos Fernández-López , Francisco Navarro , Enrique Raya , Eva Galindez-Agirregoikoa , Beatriz Arca , Roser Solans-Laqué , Arantxa Conesa , Cristina Hidalgo , Carlos Vázquez , José Andrés Román-Ivorra , Pau Lluch , Sara Manrique-Arija , Paloma Vela , Eugenio De Miguel , Carmen Torres-Martín , Juan Carlos Nieto , Carmen Ordas-Calvo , Eva Salgado-Pérez , Cristina Luna-Gomez , F. Javier Toyos-Sáenz de Miera , Nagore Fernández-Llanio , Antonio García , Carmen Larena , Natalia Palmou-Fontana , Vanesa Calvo-Río , Diana Prieto-Peña , Carmen González-Vela , Alfonso Corrales , María Varela-García , Elena Aurrecoechea , Raquel Dos Santos , Ángel García-Manzanares , Norberto Ortego , Sabela Fernández , Francisco Ortiz-Sanjuán , Montserrat Corteguera , José L. Hernández , Miguel Á. González-Gay , Ricardo Blanco Seminars in Arthritis and Rheumatism（2019）
摘要
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice
更多 查看译文
关键词
Tocilizumab, Giant cell arteritis, Biological therapy, Large-vessel vasculitis
AI 理解论文
溯源树
样例
